
Commentary|Podcasts|June 27, 2024
Pharmacy Focus: Oncology Edition- Benefits of Subcutaneous Amivantamab for Lung Cancer Treatment
The PALOMA-3 trial showed subcutaneous amivantamab was better than IV among lung cancer patients.
Advertisement
This month, we spoke with Natasha B. Leighl, BSc, MMSc, MD, Medical Oncologist at the Princess Margaret Cancer Centre in Toronto, Canada. Leighl discussed the PALOMA-3 trial results, shared at the American Society of Clinical Oncology 2024 Conference. Leighl noted that the trial compared subcutaneous and intravenous administration of amivantamab for lung cancer.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
Obinutuzumab-Bendamustine Produces High Response Rates in Chinese Patients With Indolent B-Cell Lymphomas
2
Long-Lived Monocyte-Derived Cells Found to Support Lasting Lung Immunity Against Influenza
3
State Pharmacy Boards Must Step Up Against Illegal Retatrutide
4
What Pharmacists Should Know About the Ifosfamide Shortage
5






































































































